ReviewHeliyon2021
The role of nanotechnology in current COVID-19 outbreak.
Review in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 42 citations in OpenAlex.
- A systematic review of microneedles technology in drug delivery through a bibliometric and patent overview.Heliyon · 2024Article
- Review
- New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention.Materials today. Chemistry · 2023Review
- Low-cost zeolitic carriers for delivery of hydroxychloroquine immunomodulatory agent with antiviral activity.Microporous and mesoporous materials : the official journal of the International Zeolite Association · 2022Article
- Antiviral potential of nanoparticles for the treatment of Coronavirus infections.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022Review
- Recent breakthroughs in nanostructured antiviral coating and filtration materials: a brief review.RSC advances · 2022Review
- Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles.Biotechnology reports (Amsterdam, Netherlands) · 2022Review
- Nanomaterials as Promising Theranostic Tools in Nanomedicine and Their Applications in Clinical Disease Diagnosis and Treatment.Nanomaterials (Basel, Switzerland) · 2021Review
- A comprehensive review on efficient approaches for combating coronaviruses.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 has recently become one of the most challenging pandemics of the last century with deadly outcomes and a high rate of reproduction number. It emphasizes the critical need for the designing of efficient vaccines to prevent virus infection, early and fast diagnosis by the high sensitivity and selectivity diagnostic kits, and effective antiviral and protective therapeutics to decline and eliminate the viral load and side effects derived from tissue damages. Therefore, non-toxic antiviral nanoparticles (NPs) have been under development for clinical application to prevent and treat COVID-19. NPs showed great promise to provide nano vaccines against viral infections. Here, we discuss the potentials of NPs that may be applied as a drug itself or as a platform for the aim of drug and vaccine repurposing and development. Meanwhile, the advanced strategies based on NPs to detect viruses will be described with the goal of encouraging scientists to design effective and cost-benefit nanoplatforms for prevention, diagnosis, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.